Integrated Drug Discovery
Integrated Drug Discovery
Integrated drug discovery services encompass a range of offerings designed to bolster and expedite drug development while cutting down the time and expenses required for introducing new drugs. The drug discovery process is intricate and demanding, spanning various phases such as target identification, lead discovery, optimization, preclinical, and clinical development. These comprehensive services excel in identifying potential challenges at an early stage of drug development, thereby contributing to cost savings by mitigating the expenses linked to unsuccessful drug development initiatives.
Target Identification and Target Validation
Integrated drug discovery services encompass a range of offerings designed to bolster and expedite drug development while cutting down the time and expenses required for introducing new drugs. The drug discovery process is intricate and demanding, spanning various phases such as target identification, lead discovery, optimization, preclinical, and clinical development. These comprehensive services excel in identifying potential challenges at an early stage of drug development, thereby contributing to cost savings by mitigating the expenses linked to unsuccessful drug development initiatives.
Target Identification and Target Validation
Integrated drug discovery services encompass a range of offerings designed to bolster and expedite drug development while cutting down the time and expenses required for introducing new drugs. The drug discovery process is intricate and demanding, spanning various phases such as target identification, lead discovery, optimization, preclinical, and clinical development. These comprehensive services excel in identifying potential challenges at an early stage of drug development, thereby contributing to cost savings by mitigating the expenses linked to unsuccessful drug development initiatives.
Target Identification and Target Validation
Integrated drug discovery services encompass a range of offerings designed to bolster and expedite drug development while cutting down the time and expenses required for introducing new drugs. The drug discovery process is intricate and demanding, spanning various phases such as target identification, lead discovery, optimization, preclinical, and clinical development. These comprehensive services excel in identifying potential challenges at an early stage of drug development, thereby contributing to cost savings by mitigating the expenses linked to unsuccessful drug development initiatives.
Hit Identification
High-Throughput Screening (HTS)
Cutting-edge automation and technologies such as microfluidics and lab-on-a-chip systems enable rapid assessment of an extensive library of compounds against a specific target.
Virtual Screening
Molecular docking and molecular dynamics simulations predict how compounds interact with target proteins to prioritize the most promising candidates for further evaluation.
Hit Identification
The purpose of hit identification is to pinpoint initial compounds that show potential activity against a specific target setting the stage for refinement and further evaluation. Leveraging innovative technologies like high-resolution imaging and mass spectrometry facilitates the identification of initial hit compounds. Our AI-driven approaches can also analyze large datasets to detect patterns and trends that guide informed decisions.
Hit Identification
High-Throughput Screening (HTS)
Cutting-edge automation and technologies such as microfluidics and lab-on-a-chip systems enable rapid assessment of an extensive library of compounds against a specific target.
Virtual Screening
Molecular docking and molecular dynamics simulations predict how compounds interact with target proteins to prioritize the most promising candidates for further evaluation.
Hit Identification
The purpose of hit identification is to pinpoint initial compounds that show potential activity against a specific target setting the stage for refinement and further evaluation. Leveraging innovative technologies like high-resolution imaging and mass spectrometry facilitates the identification of initial hit compounds. Our AI-driven approaches can also analyze large datasets to detect patterns and trends that guide informed decisions.
Hit Identification
High-Throughput Screening (HTS)
Cutting-edge automation and technologies such as microfluidics and lab-on-a-chip systems enable rapid assessment of an extensive library of compounds against a specific target.
Virtual Screening
Molecular docking and molecular dynamics simulations predict how compounds interact with target proteins to prioritize the most promising candidates for further evaluation.
Hit Identification
The purpose of hit identification is to pinpoint initial compounds that show potential activity against a specific target setting the stage for refinement and further evaluation. Leveraging innovative technologies like high-resolution imaging and mass spectrometry facilitates the identification of initial hit compounds. Our AI-driven approaches can also analyze large datasets to detect patterns and trends that guide informed decisions.
Hit to Lead
Hit to Lead
Medicinal Chemistry
Leveraging computational modeling and AI-driven molecular design to explore vast chemical space. Utilizing fragment-based drug design and de novo design, precisely modify hit compounds, enhancing their binding affinity and pharmacokinetic properties.
Structure based Drug Design (SBDD)
Cryo-electron microscopy (cryo-EM) and X-ray crystallography provide high-resolution structural insights into target proteins, enabling the designing of compounds that fit into binding pockets and optimized binding interactions.
Lead Identification
Lead identification is a pivotal stage aimed at delving deeper into promising hits and selecting compounds demonstrating potential activity against the target. This crucial phase involves meticulous evaluation of compound efficacy and selectivity. This essential stage entails a thorough assessment of compound effectiveness and specificity. Within lead identification, services encompass Activity Profiling, Structure-Activity Relationship (SAR) and Structure-Property Relationship (SPR) analysis, and engagement with Medicinal Chemistry.
Medicinal Chemistry
Leveraging computational modeling and AI-driven molecular design to explore vast chemical space. Utilizing fragment-based drug design and de novo design, precisely modify hit compounds, enhancing their binding affinity and pharmacokinetic properties.
Structure based Drug Design (SBDD)
Cryo-electron microscopy (cryo-EM) and X-ray crystallography provide high-resolution structural insights into target proteins, enabling the designing of compounds that fit into binding pockets and optimized binding interactions.
Lead Identification
Lead identification is a pivotal stage aimed at delving deeper into promising hits and selecting compounds demonstrating potential activity against the target. This crucial phase involves meticulous evaluation of compound efficacy and selectivity. This essential stage entails a thorough assessment of compound effectiveness and specificity. Within lead identification, services encompass Activity Profiling, Structure-Activity Relationship (SAR) and Structure-Property Relationship (SPR) analysis, and engagement with Medicinal Chemistry.
Medicinal Chemistry
Leveraging computational modeling and AI-driven molecular design to explore vast chemical space. Utilizing fragment-based drug design and de novo design, precisely modify hit compounds, enhancing their binding affinity and pharmacokinetic properties.
Structure based Drug Design (SBDD)
Cryo-electron microscopy (cryo-EM) and X-ray crystallography provide high-resolution structural insights into target proteins, enabling the designing of compounds that fit into binding pockets and optimized binding interactions.
Lead Identification
Lead identification is a pivotal stage aimed at delving deeper into promising hits and selecting compounds demonstrating potential activity against the target. This crucial phase involves meticulous evaluation of compound efficacy and selectivity. This essential stage entails a thorough assessment of compound effectiveness and specificity. Within lead identification, services encompass Activity Profiling, Structure-Activity Relationship (SAR) and Structure-Property Relationship (SPR) analysis, and engagement with Medicinal Chemistry.
Lead Optimisation & Selection
Lead Optimisation & Selection
Lead Optimisation
Lead optimization involves refining selected compounds meticulously to optimize their potency, selectivity, and pharmacokinetic attributes while minimizing adverse effects. The overarching goal of lead optimization is to foster the Development of drug candidates poised to deliver therapeutic excellence.
ADME/T Profiling
Microfluidic-based platforms and organ-on-a-chip models offer an innovative approach to assessing the ADME/T properties of lead compounds for more accurate lead selection.
In Vitro & In Vivo Pramacology
Imaging techniques to visualize the distribution and efficacy of lead compounds in vivo. Organoids, 3D cell cultures, and genetically modified animal models to enhance the predictive power of in vitro and in vivo studies.
Lead Optimisation
Lead optimization involves refining selected compounds meticulously to optimize their potency, selectivity, and pharmacokinetic attributes while minimizing adverse effects. The overarching goal of lead optimization is to foster the Development of drug candidates poised to deliver therapeutic excellence.
ADME/T Profiling
Microfluidic-based platforms and organ-on-a-chip models offer an innovative approach to assessing the ADME/T properties of lead compounds for more accurate lead selection.
In Vitro & In Vivo Pramacology
Imaging techniques to visualize the distribution and efficacy of lead compounds in vivo. Organoids, 3D cell cultures, and genetically modified animal models to enhance the predictive power of in vitro and in vivo studies.
Lead Optimisation
Lead optimization involves refining selected compounds meticulously to optimize their potency, selectivity, and pharmacokinetic attributes while minimizing adverse effects. The overarching goal of lead optimization is to foster the Development of drug candidates poised to deliver therapeutic excellence.
ADME/T Profiling
Microfluidic-based platforms and organ-on-a-chip models offer an innovative approach to assessing the ADME/T properties of lead compounds for more accurate lead selection.
In Vitro & In Vivo Pramacology
Imaging techniques to visualize the distribution and efficacy of lead compounds in vivo. Organoids, 3D cell cultures, and genetically modified animal models to enhance the predictive power of in vitro and in vivo studies.
Preclinical Candidate Selection and Development
Preclinical Candidate Selection and Development
Candidate Selection
Preclinical candidate selection involves evaluating lead compounds' safety and efficacy and preparing them for clinical trials. This stage ensures the potential for successful drug development.
Formulation Development
Appropriate formulations are at the forefront of improving solubility, extending half-life, and enabling targeted drug delivery, optimizing therapeutic outcomes.
Safety Assessment
Leveraging cutting-edge organ-on-a-chip models and micro-physiological systems, we replicate organ functions for unparalleled insights into potential adverse effects. This innovative approach enhances safety predictions and accelerates drug development, refining lead compounds for optimal efficacy and safety to lay the foundation for clinical success.
Candidate Selection
Preclinical candidate selection involves evaluating lead compounds' safety and efficacy and preparing them for clinical trials. This stage ensures the potential for successful drug development.
Formulation Development
Appropriate formulations are at the forefront of improving solubility, extending half-life, and enabling targeted drug delivery, optimizing therapeutic outcomes.
Safety Assessment
Leveraging cutting-edge organ-on-a-chip models and micro-physiological systems, we replicate organ functions for unparalleled insights into potential adverse effects. This innovative approach enhances safety predictions and accelerates drug development, refining lead compounds for optimal efficacy and safety to lay the foundation for clinical success.
Candidate Selection
Preclinical candidate selection involves evaluating lead compounds' safety and efficacy and preparing them for clinical trials. This stage ensures the potential for successful drug development.
Formulation Development
Appropriate formulations are at the forefront of improving solubility, extending half-life, and enabling targeted drug delivery, optimizing therapeutic outcomes.
Safety Assessment
Leveraging cutting-edge organ-on-a-chip models and micro-physiological systems, we replicate organ functions for unparalleled insights into potential adverse effects. This innovative approach enhances safety predictions and accelerates drug development, refining lead compounds for optimal efficacy and safety to lay the foundation for clinical success.
Contact Us
Contact Us
Contact Us
